AML 18	A Programme of Development for Older Patients with Acute Myeloid Leukaemia and High-Risk Myelodysplasia Syndrome

PATIENT RANDOMISATION NOTEPAD 2C

CPX-351 (300) vs CPX-351 (200)

Residual disease detected or unassessable for patients who received CPX-351 in course 1

Trials Office tel: 029 2251 0530 Trials Office fax: 029 2068 7501
Online Randomisation: https://trials.cardiff.ac.uk/aml-18

AML 18 Trial Number: ☐☐☐☐

[1]Patient's Initials: …… [2]DoB: DD / MMM / YYYY [3]Sex: Male / Female

[4]Hospital: …… [5]NHS/CHI No.: ……

[6]Responsible Consultant: …… [7]Consent Form 3b- version number signed: ……

[8]Person entering patient: ……..

ELIGIBILITY CHECKLIST

Inclusion Criteria:

	YES	NO
[9.1]Has the patient's disease status been confirmed as residual disease detected or unassessable?	☐	☐
[9.2]Has the patient completed 1 course of treatment?	☐	☐
[9.3]Was the patient allocated CPX-351(300) as course 1 treatment?	☐	☐
[9.4]Has the patient provided written informed consent for this randomisation?	☐	☐

Information to be obtained from HCTU
☐ **CPX-351 (300)** ☐ **CPX-351 (200)**

Date of entry: Signature: _____ Date: